These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 20166997)

  • 1. Design and application of microfluidic systems for in vitro pharmacokinetic evaluation of drug candidates.
    Maguire TJ; Novik E; Chao P; Barminko J; Nahmias Y; Yarmush ML; Cheng KC
    Curr Drug Metab; 2009 Dec; 10(10):1192-9. PubMed ID: 20166997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organ-on-a-chip technology and microfluidic whole-body models for pharmacokinetic drug toxicity screening.
    Lee JB; Sung JH
    Biotechnol J; 2013 Nov; 8(11):1258-66. PubMed ID: 24038956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hurel -- an in vivo-surrogate assay platform for cell-based studies.
    Baxter GT
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():11-8. PubMed ID: 19807199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.
    Masimirembwa CM; Bredberg U; Andersson TB
    Clin Pharmacokinet; 2003; 42(6):515-28. PubMed ID: 12793837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically Based Pharmacokinetic and Pharmacodynamic Analysis Enabled by Microfluidically Linked Organs-on-Chips.
    Prantil-Baun R; Novak R; Das D; Somayaji MR; Przekwas A; Ingber DE
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():37-64. PubMed ID: 29309256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of body-on-a-chip devices in drug and toxicity studies.
    Esch MB; King TL; Shuler ML
    Annu Rev Biomed Eng; 2011 Aug; 13():55-72. PubMed ID: 21513459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microfluidics-assisted in vitro drug screening and carrier production.
    Tsui JH; Lee W; Pun SH; Kim J; Kim DH
    Adv Drug Deliv Rev; 2013 Nov; 65(11-12):1575-88. PubMed ID: 23856409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microfluidics for drug discovery and development: from target selection to product lifecycle management.
    Kang L; Chung BG; Langer R; Khademhosseini A
    Drug Discov Today; 2008 Jan; 13(1-2):1-13. PubMed ID: 18190858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The design and fabrication of three-chamber microscale cell culture analog devices with integrated dissolved oxygen sensors.
    Sin A; Chin KC; Jamil MF; Kostov Y; Rao G; Shuler ML
    Biotechnol Prog; 2004; 20(1):338-45. PubMed ID: 14763861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human.
    Chao P; Maguire T; Novik E; Cheng KC; Yarmush ML
    Biochem Pharmacol; 2009 Sep; 78(6):625-32. PubMed ID: 19463793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics.
    Roberts SA
    Xenobiotica; 2001; 31(8-9):557-89. PubMed ID: 11569526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability.
    Cai H; Stoner C; Reddy A; Freiwald S; Smith D; Winters R; Stankovic C; Surendran N
    Int J Pharm; 2006 Feb; 308(1-2):133-9. PubMed ID: 16352407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances on Cell Culture Platforms for In Vitro Drug Screening and Cell Therapies: From Conventional to Microfluidic Strategies.
    Cardoso BD; Castanheira EMS; Lanceros-Méndez S; Cardoso VF
    Adv Healthc Mater; 2023 Jul; 12(18):e2202936. PubMed ID: 36898671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development.
    Baranczewski P; Stańczak A; Sundberg K; Svensson R; Wallin A; Jansson J; Garberg P; Postlind H
    Pharmacol Rep; 2006; 58(4):453-72. PubMed ID: 16963792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biofabrication of a three-dimensional liver micro-organ as an in vitro drug metabolism model.
    Chang R; Emami K; Wu H; Sun W
    Biofabrication; 2010 Dec; 2(4):045004. PubMed ID: 21079286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct cell writing of 3D microorgan for in vitro pharmacokinetic model.
    Chang R; Nam J; Sun W
    Tissue Eng Part C Methods; 2008 Jun; 14(2):157-66. PubMed ID: 18544030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of physicochemical and pharmacokinetic parameters in lead optimization: a physiological pharmacokinetic model based approach.
    Benjamin B; Barman TK; Chaira T; Paliwal JK
    Curr Drug Discov Technol; 2010 Sep; 7(3):143-53. PubMed ID: 20843296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microfluidic Cell Culture Platforms to Capture Hepatic Physiology and Complex Cellular Interactions.
    Bale SS; Borenstein JT
    Drug Metab Dispos; 2018 Nov; 46(11):1638-1646. PubMed ID: 30115643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.